Skip to content

Sarepta Therapeutics

US · SRPT #2853 by market cap Listed 1970
13.33 -0.84 -5.93%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:54

Price chart

Pre-market 13.94 -1.62%
After-hours 13.60 +2.03%
Overnight 14.08 -0.64%
23.2113.3313.332026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on SRPT?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -24.9% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 18.3% of float.
  • Analyst tilt is Hold.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall F

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 61.8% Better than 76%
Operating margin -29.9% Better than 11%
Net margin -32.5% Better than 10%
Return on equity -53.5% Better than 9%
Return on invested capital -28.2% Better than 11%
Momentum D+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -29.1% Better than 19%
6-month return -20.7% Better than 26%
12-month return (ex latest month) 2.8% Better than 37%
Distance below 52-week high 46.0% Better than 22%
Financial Health C-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 2.3x Better than 63%
Debt to assets 31.0% Better than 40%
Interest coverage -17.4x Better than 10%
Analyst View C+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 20.0% Better than 9%
Upside to average target 67.5% Better than 75%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -17.05%
1M -30.46%
3M -30.65%
6M -22.14%
YTD -38.06%
1Y -19.11%
3Y -83.95%
5Y -83.34%

Key statistics

Price & volume

Prev close
14.17
Open
13.92
Day range
13.25 - 14.47
Avg price
13.67
Volume
2.25M
Turnover
30.80M
Amplitude
8.58%
52-week range
13.25 - 24.68

Valuation

P/E
-1.87
P/E (TTM)
-10.33
P/B
0.93
EPS
-7.13
Net profit
-764.59M
Net assets
1.53B

Share structure

Market cap
1.43B
Float cap
1.36B
Shares out
107.24M
Float shares
102.15M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 1% of range
13.25 24.68

46.0% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-7.47M net over the window

Short interest

Shares short
19.30M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Sarepta Therapeutics (SRPT)?

Sarepta Therapeutics last traded at 13.33. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Sarepta Therapeutics's market cap?

About 1.43B.

What is the P/E ratio of Sarepta Therapeutics?

The trailing twelve-month P/E is -10.33, below its own 5-year average of 23.56 — in the middle of its historical range (42.58% percentile). See the Valuation tab for the full history.

Does Sarepta Therapeutics pay a dividend?

Sarepta Therapeutics does not currently pay a regular dividend.

Is Sarepta Therapeutics a buy according to analysts?

The consensus of 15 analysts is a Hold rating, with an average 12-month price target of 22.33, which implies 67.5% upside from the current price. This is not investment advice.

What is Sarepta Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Sarepta Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:54:28 · For reference only, not investment advice and not tailored to your situation.

Sarepta Therapeutics discussion 0 comments

Add a comment